The Journal is included in Russian and International Library and Abstract Databases
Russain Science Index (Russia)
EBSCO
DOI Registration Agency (USA)

Prediction of the results of rheumatoid arthritis therapy with leflunomide

DOI: https://doi.org/10.29296/25877305-2019-10-07
Issue: 
10
Year: 
2019

V. Saritkhala; Professor A. Yagoda, MD; Professor P. Koroy, MD Stavropol State Medical University

The investigation of the plasma level of adhesion molecules in patients with rheumatoid ar-thritis revealed that the values of a number of adhesins became normal during leflunomide therapy, especially if effective. The favorable response to treatment was associated with the high baseline blood levels of intercellular adhesion molecule-1, which is the basis for using them as predictors of successful therapy.

Keywords: 
rheumatoid arthritis
adhesion molecules
therapy
leflunomide
treatment predictors



References: 
  1. Karateev D.E., Orlova E.V. Leflunomid pri rannem revmatoidnom artrite: vkljuchenie v strategiju lechenija i perspektivy // Med. sovet. – 2017; 11: 91–6 [Karateev D. E., Orlova E. V. Leflunomide in early rheumatoid arthritis: inclusion in the treatment strategy and prospects // Meditsinskiy Sovet. – 2017; 11: 91–6 (In Russ.)]. DOI: 10.21518/2079-701X-2017-0-90-96.
  2. Smolen J., Landewé R., Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update // Ann. Rheum. Dis. – 2017; 76 (6): 960–77. DOI: 10.1136/annrheumdis-2016-210715.
  3. Zeb S., Wazir N., Waqas M. et al. Comparison of short-term efficacy of leflunomide and methotrexate in active rheumatoid arthritis // J. Postgrad. Med. Inst. – 2016; 30 (2): 177–80.
  4. Golicki D., Niewada M., Lis J. et al. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials // Pol. Arch. Wewn. – 2012; 122 (1–2): 22–32. DOI: 10.20452/pamw.1131.
  5. Mathur R., Singh H., Arya S. et al. Comparative evaluation of efficacy of leflunomide versus combination of methotrexate and hydroxychloroquine in patients of rheumatoid arthritis – an Indian experience // Indian J. Rheumatol. – 2016; 11 (2): 86–90. DOI: 10.1016/j.injr.2016.03.002.
  6. Benucci M., Saviola G., Baiardi P. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis // Int. J. Immunopathol. Pharmacol. – 2011; 1: 269–74. DOI: 10.1177/039463201102400136.
  7. Hodkinson B., Magomero R., Tikly M. Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach // Ther. Adv. Musculoskelet. Dis. – 2016; 8 (5): 172–9. DOI: 10.1177/1759720X16664324.
  8. Jagoda A.V., Sarithala V.D., Koroj P.V. Anemija pri revmatoidnom artrite: vzaimosvjaz' s gepsidinom i molekulami adgezii // Med. vestn. Severnogo Kavkaza. – 2018; 13 (2): 338–42 [Yagoda A.V., Sarithala V.J., Koroy P.V. Anemia in rheumatoid arthritis: correlation with hepcidin and adhesion molecules // Meditsinskiy vestnik Severnogo Kavkaza. – 2018; 13 (2): 338–42 (In Russ.)]. DOI: 10.14300/mnnc.2018.13044.
  9. Klimek E., Skalska A., Kwaśny-Krochin B. et al. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration // Mediators Inflamm. – 2014; 2014: 681635. DOI: 10.1155/2014/681635.
  10. Koroy P., Sarithala V., Yagoda A. Soluble molecules of immunoglobulins superfamily in rheumatoid arthritis // Medical news of North Caucasus. – 2017; 12 (3): 256–60. DOI: org/10.14300/mnnc.2017.12092.
  11. Sarithala V., Koroy P., Yagoda A. Variations in levels of intercellular adhesion molecule-1 with disease course, in rheumatoid arthritis patients // J. Clin. Diagnostic Res. – 2018; 12 (9): 18–21. DOI: 10.7860/JCDR/2018/35302.12044.
  12. Södergren A., Karp K., Boman K. et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness // Arthritis Res. Ther. – 2010; 12 (4): R158. DOI: 10.1186/ar3116.
  13. Klimiuk P., Sierakowski S., Domyslawska I. et al. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis // Scand. J. Rheumatol. – 2009; 38 (6): 439–44. DOI: 10.3109/03009740903079321.
  14. Koroy P., Sarithala V., Yagoda A. Biological therapy of rheumatoid arthritis: is real prediction of efficacy? // Medical News of North Caucasus. – 2018; 13 (3): 463–7. DOI: 10.14300/mnnc.2018.13078.
  15. Klimiuk P., Fiedorczyk M., Sierakowski S. et al. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis // Scand. J. Rheumatol. – 2007; 36 (5): 345–50. DOI: 10.1080/03009740701406460.
  16. Oranskiy S., Yeliseyeva L. Serum concentration of immune, endocrine and endothelial biomarkers in patients with rheumatoid arthritis associated with different variants of metabolic status treated with infliximab // Medical news of North Caucasus. – 2016; 11 (2): 139–42. DOI: 10.14300/mnnc.2016.11019.
  17. Shu Q., Amin M., Ruth J. et al. Suppression of endothelial cell activity by inhibition of TNF alpha // Arthritis Res. Ther. – 2012; 14 (2): R88. DOI: 10.1186/ar3812.
  18. Komarova E.B., Rebrov B.A., Knjazeva A.K. Ingibitor angiotenzinprevraschajuschego fermenta v kompleksnom lechenii revmatoidnogo artrita // Sovremennaja revmatologija. – 2017; 11 (3): 72–6 [Komarova E.B., Rebrov B.A., Knyazeva A.K. An angiotensin-converting enzyme inhibitor in the combination treatment of rheumatoid arthritis // Sovremennaya Revmatologiya. – 2017; 11 (3): 72–6 (In Russ.)]. DOI: 10/14412/1996-7012-2017-3-72-76.
  19. Canhão H., Rodrigues A., Mourão A. et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis // Rheumatology. – 2012; 51 (11): 2020–6. DOI: 10.1093/rheumatology/kes184.
  20. Tanaka H., Kanazawa M., Kawakami T. Efficacy and safety of tocilizumab therapy in rheumatoid arthritis: prevalence and predictive factors of sustained remission // Ann. Rheum. Dis. – 2013; 72: A453. DOI: 10.1136/annrheumdis-2013-eular.1363